Cancer therapies have advanced tremendously throughout the last decade, yet multiple
factors still hinder the success of the different cancer therapeutics. The traditional therapeutic …

Effective drug delivery and prevention of postoperative recurrence are significant challenges
for current glioblastoma (GBM) treatment. Poor drug delivery is mainly due to the presence …

Glioblastoma (GBM) remains the most lethal malignant tumours. Gboxin, an oxidative
phosphorylation inhibitor, specifically restrains GBM growth by inhibiting the activity of F0F1 …

Glioblastoma (GBM) is an aggressive brain cancer with an immunosuppressive tumor
microenvironment. Here, a copper-based nanoplatform BSO-CAT@ MOF-199@ DDM …

Developing efficient cancer treatment modalities is crucial, given the tens of thousands of
deaths that cancer causes each year. Although there are various treatment modalities …

Glioblastoma (GBM) is the most devastating brain tumor and highly resistant to conventional
chemotherapy. Herein, we introduce biomimetic nanosonosensitizer systems (MDNPs) …

Ultrasound, featuring deep tissue penetration and noninvasiveness, offers a new opportunity
to activate functional materials in a tumor‐selective manner. However, very few direct …

To improve the drug loading, tumor targeting, and delivery simplicity of hydrophilic drugs, we
propose a supramolecular assembly strategy that potentially benefits a wide range of …

Existing solid‐nanoparticle‐based drug delivery systems remain a great challenge for
glioblastoma chemotherapy due to their poor capacities in crossing the blood–brain …

The crossing of blood–brain barrier (BBB) is essential for glioblastoma (GBM) therapy, and
homotypic targeting is an effective strategy to achieve BBB crossing. In this work, GBM …